Atrial flutter is a supraventricular tachycardia frequently found in association with atrial fibrillation. It is, however, an entity distinct from atrial fibrillation. Atrial flutter is the result of macro reentry involving the entire atrium in the circuit.
Sx & Dx: (REF: Cheng-Zaas: The Osler Medical
Handbook, 1st ed. 2003)
Atrial flutter often has the same symptoms as atrial fibrillation. The atrial rate is typically between 250 and 350 beats/min, with resultant 2:1 or 4:1 atrioventricular conduction block. Diagnosis is based on the 12-lead ECG. The blocked flutter waves may not be readily apparent on 12-lead ECG because they may be masked by the QRS complex. The presence of a regular, narrow complex tachycardia at 150 beats/min should raise suspicion for the presence of atrial flutter and prompt a close comparison of the ECG with a prior sinus rhythm ECG to look for blocked flutter waves.
Acute management of atrial flutter does not differ significantly
from that of atrial fibrillation.
Patients with hemodynamic compromise should undergo emergency cardioversion. Stable patients can be treated acutely with ß-blockers or calcium channel blockers for rate control.
Atrial flutter can be cured with radiofrequency catheter ablation.
Acute Pharmacologic Rx for hemodynamically stable atrial flutter patient:
IV diltiazem or digoxin Rx (start 0.5-1mg IV) may be tried to slow the ventricular rate and convert flutter to fibrillation.
Atrial flutter is frequently associated with intermittent atrial
It may be prudent to anticoagulate patients with atrial flutter and coexisting medical disorders (e.g., diabetes mellitus, hypertension, cardiac disease) before cardioversion. Anticoagulation should also be considered for all patients with atrial flutter who are older than 65 years of age.
Rx of Chronic Atrial Flutter (often quite refractory to pharmacologic Rx & tends to recur shortly after an electrical cardioversion)
For patients with recurrent, symptomatic atrial flutter, first-line therapy should be ablation rather than antiarrhythmic drug therapy. In a randomized study 61 patients with atrial flutter were assigned to primary treatment with catheter ablation or antiarrhythmic drug (AAD) therapy. At the end of 1 year, atrial flutter had recurred in 6% of the ablation group and 93% of the AAD group; atrial fibrillation occurred in 29% of the ablation group and 60% of the AAD group. Hospitalizations were also less frequent in the patients treated primarily with ablation (22% versus 63%).